Since 2000, the FDA has explicitly described the importance of radiographic evaluation in spinal studies in primary and secondary endpoints.
The FDA granted RMAT designation to DiscGenics’ Injectable Disc Cell Therapy for degenerative disc disease.
MMI co-founder, Dr. John Hipp, was recognized for his outstanding contributions to spine basic research.
In the face of an aging population and the demand for cost-effective solutions, spine surgeons hold the targeted insight necessary to determine which devices will find a warm welcome in the market.
A recent study took advantage of Medical Metrics state-of-the-art Quantitative Motion Analysis, or QMA®, software to track the motion of cervical disk replacements with extreme precision.
